Study reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2


Transmission electron micrograph of SARS-CoV-2 virus particles isolated from the patient. Color-enhanced images captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

Due to the COVID-19 pandemic and the recurrence of infection with other respiratory RNA viruses such as respiratory syncytial virus (RSV) in children, there is an urgent need to develop a wide range of orally administrable antiviral therapeutics.

In a study published online on December 2nd ChemistryResearchers at the Institute of Biomedical Sciences, Georgia State University have found a new candidate ribonucleoside analog with potent antiviral activity against intracellular SARS-CoV-2, RSV and other respiratory RNA viruses, 4′. -Fluorosides (4′-FlU) report cultures, human organoids and various animal models when orally administered once daily.

“Mechanistically, 4′-FlU shows that it is in a different class than molnupiravir, which is currently under consideration for regulatory approval,” said the study’s senior author and prominent university professor. Yes, said Dr. Richard Plumper, director of the Center for Translation and Antiviral Research. In Georgia. “4′-FlU does not act as a mutagen, but it induces termination of viral polymerases and ceases replication of the viral genome. An urgent expansion of therapeutic weapons against SARS-CoV-2 and 4′-FlU. There is a need. Promise as a companion drug. “

In this study, 4′-FlU was used against various SARS-CoV-2 mutants of concern in ferrets, which have emerged as the primary model for drug testing, and RS virus With the mouse. Researchers have found that the drug strongly blocked SARS-CoV-2 replication, including ferret gamma and delta variants, and effectively suppressed RSV loading in the lungs of mice.

“4′-FlU is the only orally available antiviral candidate currently being developed for SARS-CoV-2 and is active when administered once daily,” said the lead author of the study. Yes, Dr. .. “It should be a key asset in ensuring outpatient compliance,” said Plemper’s laboratory at the Institute of Biomedical Sciences.

This study of 4′-FlU resulted from a collaborative study between a team at Georgia State University and researchers at Emory University and the Texas Institute of Biomedical Sciences. This study was funded by a Public Health Services Grant from the National Institute of Health Sciences / National Institute of Allergic Infectious Diseases to Georgia State University.

The co-author of this study is J. Sourimant, CM Lieber, M. Includes Aggarwal, RM Cox, JD Wolf, J.-J. Yeong, M. of Georgia State University. Toots, RK Plemper. C. Ye and L. Martinez-Sobrido of the Texas Institute of Biomedical Sciences; Z. Stickher, AA Kolykhalov, GR Bluemling, MG Natchus, GR Painter of Emory University.

Oral drugs block SARS-CoV-2 infection

For more information:
Chemistry (2021). DOI: 10.1126 / science.abj5508

Quote: The study was obtained from December 2, 2021 for activity against SARS-CoV-2 (2021, December 2). We are reporting a new broad spectrum antiviral class with drug class-sars-cov-.html

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.

Study reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2 Source link Study reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2

The post Study reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2 appeared first on California News Times.


Please enter your comment!
Please enter your name here

Share post:


More like this

ETH 2.0 vision meets another roadblock but validators continue their march

Ethereum, the largest altcoin has continued to take measures...

Studies suggest that Americans are still suspicious of EVs

Plugin vehicles are popular in Europe, accounting for 21%...